Texas A&M Vaccine Manufacturing Contract Shows that cGMP Manufacturing of COVID-19 Vaccines Can Start in Five Months 

A $265 million COVID-19 vaccine manufacturing contract between the Department of Health and Human Services (HHS) and the Texas A&M University System (TAMUS) to manufacture the Novavax and other COVID-19 vaccines demonstrates that a manufacturing facility can be retrofitted to… Continue Reading

KEI submission to Canada Standing Committee on International Trade and Investment Policy: Concerning COVID-19

Brief to Standing Committee on International Trade and Investment Policy: Selected Consideration Concerning COVID-19 Vaccines Knowledge Ecology International James Love and Arianna Schouten 30 April 2021 This brief will discuss (1) the scope and purpose of the proposed World Trade… Continue Reading

41 Canadian Experts Request Amendment to Schedule 1 of the Patent Act to include COVID-19 vaccines

On April 27th, a letter signed by 41 Canadian experts was sent to the Prime Minister of Canada, the Minister of Innovation, Science & Industry, and the Minister of Health. The letter requests the amendment of Schedule 1 of the… Continue Reading

COVID-related Needle and Syringe Contracts

United States of America Becton Dickinson and Company- needle production. DoD/ASPR/BARDA-Becton Dickinson Contract W911SR2030001. July 1, 2020. (Version obtained via FOIA lawsuit in March 2021) DoD/ASPR/BARDA-Becton Dickinson Contract W911SR2030001. July 1, 2020. (Version obtained via HHS Reading Room in October… Continue Reading

KEI Comments Regarding NIH Exclusive License to Memorial Sloan Kettering Cancer Center

(Update: The NIH provided a response to our comments on April 15, 2021.) Knowledge Ecology International (KEI) submitted comments on April 14, 2021 to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of Exclusive Patent… Continue Reading

KEI Comments on NIH Proposed Exclusive License to Iovance for Cancer Cell Therapy

On Friday March 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy” (86 FR 11548). The technology is… Continue Reading

NIST Proposed Revisions to Bayh-Dole Act Regulations

New: Biden White House Executive Order opposes change in Bayh-Dole March-In regulations. (KEI has an email list to discuss this issue here: http://lists.keionline.org/mailman/listinfo/bayh-dole-regulations_lists.keionline.org) The Department of Commerce’s National Institute of Standards and Technology (NIST) published on January 4, 2021, a… Continue Reading